Suppr超能文献

既往感染或接种疫苗的员工中 SARS-CoV-2 感染的发生率。

Incidence of SARS-CoV-2 infection among previously infected or vaccinated employees.

机构信息

Department of Medicine, University of California Los Angeles, Los Angeles, 90095.

Curative Inc., San Dimas, CA.

出版信息

Int J Infect Dis. 2022 May;118:21-23. doi: 10.1016/j.ijid.2022.02.015. Epub 2022 Feb 10.

Abstract

INTRODUCTION

We aimed to determine the incidence of SARS-CoV-2 infection among individuals with a previous SARS-CoV-2 infection versus vaccinated individuals.

METHODS

In March 2020, a SARS-CoV-2 testing company began routinely screening its workforce for SARS-CoV-2 with a PCR test. On December 15, 2020, vaccination with either the BNT162b2 or mRNA-1273 vaccines became available. Routine screening has continued through July 2021. We compared the incidence of SARS-CoV-2 infection between people who were SARS-CoV-2 naïve and unvaccinated, people with prior COVID-19 without vaccination, and people vaccinated without prior COVID-19. Incidence in 100 person-years with 95% confidence intervals (95% CIs) was calculated with the Poisson Exact equation. The incidence rate ratio (IRR), the ratio of confirmed COVID-19 cases per 100 person-years of follow-up with 95% CIs, was used as a measure of association between groups. Analyses were performed on StataSE.

RESULTS

The median age of employees was 29.0 years (interquartile range: 23.6, 39.9). During the observation period, 258 SARS-CoV-2 incident infections were identified. The naïve, unvaccinated group had a SARS-CoV-2 incidence of 25.9 per 100 person-years (95% CI: 22.8-29.3). The previously infected, unvaccinated group had an incidence of 0 per 100 person-years (95% CI: 0-5.0). The vaccinated group had an incidence of 1.6 per 100 person-years (95% CI: 0.04-4.2).

CONCLUSION

We found a strong association between prior SARS-CoV-2 infection and/or vaccination for SARS-CoV-2 with either the BNT162b2 or mRNA-1273 vaccines and the reduced incidence of SARS-CoV-2 infection when compared with those naïve and/or unvaccinated to SARS-CoV-2.

摘要

简介

本研究旨在确定既往感染 SARS-CoV-2 与接种疫苗人群中 SARS-CoV-2 感染的发生率。

方法

2020 年 3 月,一家 SARS-CoV-2 检测公司开始常规使用 PCR 检测对其员工进行 SARS-CoV-2 检测。2020 年 12 月 15 日,可使用 BNT162b2 或 mRNA-1273 疫苗进行接种。常规筛查一直持续到 2021 年 7 月。我们比较了 SARS-CoV-2 感染在 SARS-CoV-2 初治且未接种疫苗人群、既往 COVID-19 未经接种疫苗人群和既往 COVID-19 接种疫苗人群中的发生率。采用泊松精确方程计算 100 人年的发病率及其 95%置信区间(95%CI)。发病率比值(IRR),即每 100 人年随访中确诊 COVID-19 病例的比例及其 95%CI,作为组间关联的衡量指标。分析在 StataSE 上进行。

结果

员工的中位年龄为 29.0 岁(四分位间距:23.6,39.9)。在观察期间,共发现 258 例 SARS-CoV-2 感染。初治且未接种疫苗组的 SARS-CoV-2 发病率为 25.9/100 人年(95%CI:22.8-29.3)。既往感染且未接种疫苗组的 SARS-CoV-2 发病率为 0/100 人年(95%CI:0-5.0)。接种疫苗组的 SARS-CoV-2 发病率为 1.6/100 人年(95%CI:0.04-4.2)。

结论

我们发现既往 SARS-CoV-2 感染和/或接种 BNT162b2 或 mRNA-1273 疫苗与 SARS-CoV-2 之间存在很强的关联,与 SARS-CoV-2 初治且未接种疫苗的人群相比,SARS-CoV-2 感染的发生率降低。

相似文献

1
Incidence of SARS-CoV-2 infection among previously infected or vaccinated employees.
Int J Infect Dis. 2022 May;118:21-23. doi: 10.1016/j.ijid.2022.02.015. Epub 2022 Feb 10.
6
Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore.
JAMA Netw Open. 2022 Mar 1;5(3):e222940. doi: 10.1001/jamanetworkopen.2022.2940.
7
Impact of national Covid-19 vaccination Campaign, South Korea.
Vaccine. 2022 Jun 9;40(26):3670-3675. doi: 10.1016/j.vaccine.2022.05.002. Epub 2022 May 8.
9
Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study.
Clin Microbiol Infect. 2022 Mar;28(3):398-404. doi: 10.1016/j.cmi.2021.11.011. Epub 2021 Nov 25.

引用本文的文献

2
SARS-CoV-2-The Role of Natural Immunity: A Narrative Review.
J Clin Med. 2022 Oct 25;11(21):6272. doi: 10.3390/jcm11216272.
4
SARS CoV-2 reinfection rate is higher in the Omicron variant than in the Alpha and Delta variants.
Ir J Med Sci. 2023 Apr;192(2):751-756. doi: 10.1007/s11845-022-03060-4. Epub 2022 Jun 17.
6
Protective immunity after recovery from SARS-CoV-2 infection.
Lancet Infect Dis. 2022 Jan;22(1):12-14. doi: 10.1016/S1473-3099(21)00676-9. Epub 2021 Nov 8.
7
A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection.
Eval Health Prof. 2021 Dec;44(4):327-332. doi: 10.1177/01632787211047932. Epub 2021 Sep 30.

本文引用的文献

1
CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants.
Open Forum Infect Dis. 2021 Mar 30;8(7):ofab143. doi: 10.1093/ofid/ofab143. eCollection 2021 Jul.
4
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765. Epub 2021 Feb 24.
5
T cell response to SARS-CoV-2 infection in humans: A systematic review.
PLoS One. 2021 Jan 25;16(1):e0245532. doi: 10.1371/journal.pone.0245532. eCollection 2021.
6
Evolution of antibody immunity to SARS-CoV-2.
Nature. 2021 Mar;591(7851):639-644. doi: 10.1038/s41586-021-03207-w. Epub 2021 Jan 18.
8
Covid-19: Do many people have pre-existing immunity?
BMJ. 2020 Sep 17;370:m3563. doi: 10.1136/bmj.m3563.
9
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.
Nature. 2020 Aug;584(7821):457-462. doi: 10.1038/s41586-020-2550-z. Epub 2020 Jul 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验